Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Copper→

Copper Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
7440-50-8
Molecular formula
Cu
Molecular weight
63.55 g/mol
Drug class
Essential trace elementcopper replacement and nutritional mineral
Mechanism of action
Copper is a cofactor for numerous cuproenzymes, including cytochrome c oxidase, lysyl oxidase, dopamine beta-hydroxylase and superoxide dismutase, supporting mitochondrial respiration, connective-tissue formation, neurotransmitter synthesis and antioxidant defence.
Indications / reported uses
  • Prevention and treatment of copper deficiency, including deficiency due to malabsorption, prolonged parenteral nutrition or inherited copper-transport disorders using the appropriate formulation and route

Sources: NIH Office of Dietary Supplements — Copper fact sheet · NLM MeSH — Copper · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Copper Environmental Risk Assessment (ERA) (the Copper ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.